Skip to main content

Evotaz FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 28, 2021.

FDA Approved: Yes (First approved January 29, 2015)
Brand name: Evotaz
Generic name: atazanavir and cobicistat
Dosage form: Tablets
Company: Bristol-Myers Squibb Company
Treatment for: HIV Infection

Evotaz (atazanavir and cobicistat) is a two-drug combination of atazanavir, a human immunodeficiency virus (HIV-1) protease inhibitor, and cobicistat, a CYP3A inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV‑1infection in adults and pediatric patients weighing at least 35 kg.

Development timeline for Evotaz

Jan 29, 2015Approval FDA Approves Evotaz (atazanavir and cobicistat) for HIV-1 Infection in Adults
Apr 14, 2014Bristol-Myers Squibb Submits NDA to FDA for Fixed-Dose Combination of Atazanavir Sulfate with Cobicistat

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.